Danish Consumer Durables Stock News

Danske Bank (CPSE:DANSKE) is back in focus after raising its 2026 net profit guidance to DKK 23b to DKK 25b and targeting around 14% return on equity, alongside fresh second quarter earnings. See our latest analysis for Danske Bank. At a share price of DKK362.4, Danske Bank has seen its 1 month share price return of 5.13% build on a 3 month gain of 10.02%. The 1 year total shareholder return of 52.45% and 5 year total shareholder return of 355.31% point to strong longer term momentum around...

How Alm. Brand’s latest earnings report frames the stock today Alm. Brand (CPSE:ALMB) recently reported its second quarter and first half 2026 earnings, with net income and earnings per share materially lower than the prior year, putting the stock under closer investor scrutiny. See our latest analysis for Alm. Brand. The Alm. Brand share price has risen 12.19% over the past 90 days and 4.60% over the past month, yet its year to date share price return is still down 9.46%. However, the 5 year...

Novo Nordisk (CPSE:NOVO B) is back in focus after European regulators cleared its once daily Wegovy pill, and Crux announced a US employer-focused collaboration to widen access to its anti obesity medications. See our latest analysis for Novo Nordisk. These Wegovy updates have landed while Novo Nordisk’s stock has shown strong recent momentum, with a 90 day share price return of 23.14% but a weaker 1 year total shareholder return, which is down 24.28%. If this obesity and diabetes story has...

Demant (CPSE:DEMANT) has launched a new cosmetic hearing aid that aims to strengthen its position in hearing healthcare at a time when competition from Sonova is intensifying in the largest hearing aid category. See our latest analysis for Demant. Against this product launch backdrop, Demant's share price has gained 39.2% over the past 90 days and 30.46% year to date to DKK278.4. Longer term total shareholder returns have been modest, including a 3% return over three years and a 28.06%...

Rising trade tensions between China and the EU, a China EU trade surplus up 24% year on year in the first half, and talk of tougher tariffs are putting supply chains and export heavy business models under fresh scrutiny. For investors, this sharpens the focus on European reshoring and nearshoring, where production and sourcing sit closer to end markets rather than relying heavily on China. This article looks at 3 stocks from a European Industrial Reshoring screener that are directly exposed...

European supply chains are being reshaped as the China EU trade surplus climbs 24% year on year in 2024 and Brussels pushes for “tangible results” by October. For investors, that tension can create both risks and openings, especially where reshoring, nearshoring, and diversification themes intersect with listed stocks. This article focuses on three European companies from manufacturing, logistics, and technology that are exposed to the latest China EU trade headlines, and that could stand to...

DSV earnings and humanitarian activity draw investor focus DSV (CPSE:DSV) is in the spotlight after reporting second quarter 2026 results that combined higher sales with slightly lower net income, alongside participation in a large humanitarian airlift to earthquake hit communities in Venezuela. See our latest analysis for DSV. Despite the latest earnings and humanitarian airlift drawing attention, DSV's 1 year total shareholder return is down 6.44% and its share price is down 9.47% year to...

It's been a sad week for DSV A/S ( CPH:DSV ), who've watched their investment drop 14% to kr.1,449 in the week since...

Novo Nordisk recently sued Eli Lilly in a U.S. federal court, alleging that Lilly’s television and digital ads for Zepbound and Mounjaro use outdated clinical data and unfair dosing comparisons to overstate their advantages versus Wegovy and Ozempic in obesity and diabetes treatment. The case puts drug marketing standards for GLP‑1 therapies under the spotlight, with the outcome potentially influencing how companies communicate head‑to‑head efficacy in a highly competitive, high-stakes...

A.P. Møller - Mærsk (CPSE:MAERSK B) stock is in focus after the company committed $100 million to a new 617,000-square-foot fulfillment hub near Boston, tailored for a single large e-commerce customer. See our latest analysis for A.P. Møller - Mærsk. This logistics expansion comes as A.P. Møller - Mærsk’s share price shows solid momentum, with a 30 day share price return of 6.41% and a year to date share price return of 16.47%, alongside a 1 year total shareholder return of 29.52% that...

Embla Medical hf. ( CPH:EMBLA ) last week reported its latest second-quarter results, which makes it a good time for...

Why FLSmidth stock is back in focus after leadership moves FLSmidth (CPSE:FLS) has drawn fresh attention after appointing Kristoffer Hessedahl as Chief Strategy & M&A Officer and confirming Line Berg Madsen as Group General Counsel, both joining its Executive Leadership Team. The newly created strategy and M&A role, together with elevating the legal function, points to a clearer focus on portfolio decisions, deal activity and governance. These are all areas investors often watch closely in...

DSV (CPSE:DSV) has just posted Q2 2026 results with revenue of DKK76.7b and basic EPS of DKK9.5, setting the tone for how investors will read the latest quarter against a year of mixed signals. The company has seen quarterly revenue move from DKK61.0b in Q2 2025 to DKK76.7b in Q2 2026, while basic EPS shifted from DKK9.9 to DKK9.5 over the same period. This provides a clear snapshot of how the top and bottom lines are tracking into this year. With trailing net profit margins currently thinner...

As the European markets navigate a landscape marked by mixed economic signals and fluctuating oil prices, investors are keenly observing the performance of dividend stocks. With inflation rates in the eurozone showing signs of moderation yet remaining above target, identifying reliable income-generating stocks becomes crucial for those looking to balance risk and reward amidst ongoing market volatility.

Embla Medical hf (CPSE:EMBLA) has put up a solid Q2 2026 print, with revenue of US$258.6 million and basic EPS of US$0.069, building on a trailing twelve month profile that includes US$984.5 million in revenue, US$93.9 million in net income excluding extra items and basic EPS of about US$0.219. Over the past six reported quarters, the company has seen revenue move from US$202.8 million in Q1 2025 to US$258.6 million in Q2 2026, while quarterly basic EPS has ranged between US$0.028 and...

Novo Nordisk (CPSE:NOVO B) has filed a federal lawsuit in the United States against Eli Lilly. The company alleges Eli Lilly used misleading advertising for its weight loss drugs, focusing on outdated dosage comparisons. The case centers on GLP-1 based obesity and diabetes treatments, an area of intense competition between the two companies. Novo Nordisk is a major player in GLP-1 based therapies for obesity and diabetes, an area that has drawn significant attention from patients,...

As you might know, Danske Bank A/S ( CPH:DANSKE ) just kicked off its latest quarterly results with some very strong...

Why Ørsted Stock Is Back in Focus After a Major Supply Deal Good Energy has signed the largest energy supply deal in its 26 year history with Ørsted (CPSE:ORSTED), a long term power purchase agreement that gives investors a fresh data point on Ørsted’s commercial pipeline. See our latest analysis for Ørsted. The Ørsted share price has gained 18.48% year to date, with shorter term momentum positive on a 1 day, 7 day and 30 day basis. However, the 1 year total shareholder return is down 10.95%...

Danske Bank (CPSE:DANSKE) opened Q2 2026 with income momentum, reporting revenue of DKK14.9b and basic EPS of DKK7.6. Over recent quarters the bank has seen revenue move from DKK13.7b in Q2 2025 to DKK15.2b in Q4 2025, while quarterly EPS has ranged between roughly DKK6.6 and DKK7.7, giving investors a consistent read on earnings power even as market expectations shift. With a cost to income ratio that sits in the low 40s and solid profitability metrics, the latest results put the focus...

The dispute between Panama and China is shaking up global shipping, and that matters if you own or are considering shipping and logistics stocks. Detentions of Panama flagged vessels at Chinese ports, ships exiting the Panama registry, and tighter financing conditions are all feeding through to real operational risks. This article looks at three stocks from the Global Shipping Companies Impacted by Panama China Dispute screener that appear more exposed to the fallout. None looks like a clear...

As geopolitical tensions and energy market volatility continue to impact the European markets, the pan-European STOXX Europe 600 Index recently experienced a decline of 1.79%. In this environment, investors may find value in dividend stocks, which can offer a steady income stream and potentially provide some stability amidst market fluctuations.

Gyldendal (CPSE:GYLD B) has reported its H1 2026 numbers with trailing 12 month revenue of DKK856.1 million and basic EPS of DKK54.92, supported by net income of DKK55.53 million. The company has seen revenue move from DKK390.3 million in H2 2024 to DKK355.7 million in H1 2025 and DKK443.0 million in H2 2025, while basic EPS shifted from DKK27.83 to DKK3.69 and then DKK36.45 over those periods. This sets up the latest figures against a backdrop of stronger margins and higher...

Tryg (CPSE:TRYG) has reported Q2 2026 revenue of DKK11.2 billion and basic EPS of DKK1.42, with net income excluding extra items of DKK849 million setting the tone for this earnings update. The company has seen quarterly revenue fluctuate in a tight band between DKK10.5 billion and DKK11.2 billion over the past six quarters, while basic EPS has moved from DKK1.81 in Q1 2025 up to DKK2.50 in Q2 2025 and then to DKK1.42 in the latest quarter. This gives investors a clearer view of how profits...

Novo Nordisk stock has pulled back sharply over the past year, yet the shares still screen as undervalued on earnings. This sets up a clear tension between recent price weakness and what the valuation checks suggest. Over the past 5 years, Novo Nordisk has returned 33.4%, which still points to a solid long term gain despite a tough recent stretch. Expectations around GLP-1 weight loss and diabetes treatments, helped by moves such as Medicare’s GLP-1 Bridge program, can support higher...